NCT02251990View on ClinicalTrials.gov

Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)

PHASE3CompletedINTERVENTIONAL
Enrollment

489

Participants

Timeline

Start Date

January 28, 2015

Primary Completion Date

September 27, 2016

Study Completion Date

April 10, 2017

Conditions
Hepatitis C
Interventions
DRUG

Grazoprevir/Elbasvir

FDC tablet containing 100 mg of grazoprevir and 50 mg of elbasvir taken q.d. by mouth for 12 weeks.

DRUG

Placebo

Placebo tablet matching grazoprevir/elbasvir FDC tablet taken q.d. by mouth for 12 weeks.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02251990 - Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067) | Biotech Hunter | Biotech Hunter